Select a Cancer Type:
Myeloma
Myeloma
RELATED ARTICLES
Tecvayli Boosts Survival in Relapsed Multiple Myeloma: MajesTEC-9 Trial
May 30, 2026
ASCO 2026: MajesTEC-9 trial shows Tecvayli cuts death risk by 40% and improves outcomes in relapsed/refractory multiple myeloma patients.
.png?fit=crop&auto=format)
Study Identifies Why Multiple Myeloma May Return After Immunotherapy
April 17, 2026
Study finds how multiple myeloma cells adapt to immunotherapy, helping explain why patients relapse and guiding personalized treatment approaches.
Living With the Unknown: Jonathan Gluck on Multiple Myeloma and Learning to Navigate Uncertainty
March 31, 2026
Author and multiple myeloma survivor Jonathan Gluck shares how an unexpected diagnosis reshaped his identity and approach to living with uncertainty.
Breaking Down Bispecific Antibodies and Their Shift to Earlier Lines of Treatment
March 17, 2026
Dr. Joseph Mikhael, chief medical officer of the International Myeloma Foundation, provided updates from the front lines of treatment advancement.
.jpg?fit=crop&auto=format)
Mezigdomide Combo Delays Progression in Multiple Myeloma Phase 3 Trial
March 09, 2026
The SUCCESSOR-2 study shows MeziKd improves progression-free survival for relapsed multiple myeloma patients previously treated with anti-CD38 drugs.
.jpg?fit=crop&auto=format)
Multiple Myeloma Clinical Trial Led to More Than Four Years of Remission
March 04, 2026
Survivor Julie Cohen discusses her experience with cevostamab, managing CRS side effects, and reaching MRD-negative status through a clinical trial.
Advertisement
Advertisement